Molecular Predictors of Locoregional Recurrence in Breast Cancer: Ready for Prime Time?

Abstract

tumor recurrence and locoregional recurrences in patients treated by breastconserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466-2473, 2009 20. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997 21. Chagpar A, Kuerer HM, Hunt KK, et al: Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: Implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys 57:128-135, 2003 22. Cefaro GA, Genovesi D, Marchese R, et al: Predictors of local recurrence after conservative surgery and whole-breast irradiation. Breast Cancer Res Treat 98:329-335, 2006 23. Horst KC, Smitt MC, Goffinet DR, et al: Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer 5:425-438, 2005 24. Nuyten DS, Kreike B, Hart AA, et al: Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62, 2006 25. Carlson RW, Brown E, Burstein HJ, et al: NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4:S1-S26, 2006 (suppl 1) 26. Simes RJ, Coates AS: Patient preferences for adjuvant chemotherapy of early breast cancer: How much benefit is needed? J Natl Cancer Inst Monogr 30:146-152, 2001 27. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006 28. Mongan JJ, Ferris TG, Lee TH: Options for slowing the growth of health care costs. N Engl J Med 358:1509-1514, 2008 29. Iglehart JK: Prioritizing comparative-effectiveness research: IOM recommendations. N Engl J Med 361:325-328, 2009 30. Asad J, Jacobson AF, Estabrook A, et al: Does Oncotype DX recurrence score effect management of patients with early stage breast cancer. Am J Surg 196:527-529, 2008 31. Oratz R, Paul D, Cohn AL, Sedlacek SM: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. Journal of Oncology Practice 3:182-186, 2007 32. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109: 1011-1018, 2007 33. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008 34. Paik S, Tang G, Fumagalli D: An ideal prognostic test for estrogen receptor-positive breast cancer? J Clin Oncol 26:4058-4059, 2008